El Bairi, K;
Haynes, HR;
Blackley, E;
Fineberg, S;
Shear, J;
Turner, S;
de Freitas, JR;
... Bautista, V; + view all
(2021)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
npj Breast Cancer
, 7
, Article 150. 10.1038/s41523-021-00346-1.
Preview |
Text
s41523-021-00346-1.pdf - Published Version Download (2MB) | Preview |
Abstract
The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.
| Type: | Article |
|---|---|
| Title: | The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/s41523-021-00346-1 |
| Publisher version: | https://doi.org/10.1038/s41523-021-00346-1 |
| Language: | English |
| Additional information: | This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10140903 |
Archive Staff Only
 |
View Item |
